Anthem Biosciences Limited
(Formerly known as Anthem Biosciences Pvt. Ltd.)
49, F1 & F2, Canara Bank Road,
Bommasandra Industrial Area, Phase - I
Bommasandra. Bengaluru - 560 099
Karnataka, India
CIN : L24233KA2006PLC039703
Tel : + 91 80 6672 4000
www.anthembio.com

Date: November 03, 2026

To,
BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544449

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Subject: Outcome of the Board Meeting held on Tuesday, November 03, 2026

Dear Sir/Ma'am

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), we would like to inform you that the Board of Directors of Anthem Biosciences Limited *(formerly known as Anthem Biosciences Private Limited)* ("Company") at their meeting held on Tuesday, November 03, 2026 which commenced at 2.30 p.m. and concluded at 03:45 p.m. have inter-alia, approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of Statutory Auditors for the quarter and half year ended September 30, 2026. The said financials results were duly reviewed and recommended by Audit Committee at its meeting held on same day to the Board.

A copy of the said Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Statutory Auditors are enclosed herewith and the extract of the results will be published in the newspapers as required under Regulation 47(1) of SEBI LODR Regulations.

The above intimation is also available on the Company's website at https://anthembio.com/investors/.

We request you to kindly take the same on record.

Thanking you,
Yours truly,
For Anthem Biosciences Limited
(*Formerly known as Anthem Biosciences Private Limited*)

DIVYA PRASAD
Digitally signed by DIVYA PRASAD
Date: 2026.11.03 17:46:28 +05'30'

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438

S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants

12th Floor
"UB City" Canberra Block
No. 24, Vittal Mallya Road
Bengaluru - 560 001, India
Tel : +91 80 6648 9000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) (the "Company") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. The comparative financial information of the Company for the quarter ended June 30, 2026, quarter and period ended September 30, 2025, included in these standalone financial results were reviewed by the predecessor auditor and the financial statements of the Company for the year ended March 31, 2026, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those financial information on July 21, 2026, November 08, 2025 and May 19, 2026 respectively.

For S.R. Batliboi & Associates LLP
Chartered Accountants
ICAI Firm registration number: 101049W/E300004

Rajeev Kumar

per Rajeev Kumar
Partner
Membership No.: 213803

S.R. Batliboi & Associates LLP Bengaluru

Unique Document Identification Number: 26213803WFZXRS7650

Place: Bengaluru
Date: November 03, 2026

ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED)

Corporate Identity Number: L24233KA2006PLC039703

Registered and Corporate Office: No 49, F1 and F2, Canara Bank Road, Bommasandra Industrial Area, Phase-I, Bommasandra, Bangalore-560099, Karnataka India.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half year ended September 30, 2026

(₹. in Million)

Particulars	Quarter ended			Half year ended		Year ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	5,721.08	3,838.42	5,527.03	9,559.50	10,913.71	20,942.99
Other income	646.95	286.00	533.22	932.95	803.93	1,770.88
Total income	**6,368.03**	**4,124.42**	**6,060.25**	**10,492.45**	**11,717.64**	**22,713.87**
Expenses						
Cost of materials consumed	1,934.43	1,449.45	2,037.12	3,383.88	3,661.07	6,967.51
Changes in inventories of finished goods and work-in-progress	(109.53)	(23.64)	220.98	(133.17)	907.70	986.91
Employee benefits expense	743.02	727.79	626.33	1,470.81	1,310.41	2,624.63
Finance costs	30.63	7.63	22.56	38.26	39.15	67.08
Depreciation and amortisation expense	222.14	223.10	239.20	445.24	465.33	995.65
Other expense	506.17	376.49	381.04	882.66	811.58	1,801.25
Total expense	**3,326.86**	**2,760.82**	**3,527.23**	**6,087.68**	**7,195.24**	**13,443.03**
Profit before exceptional items and tax	**3,041.17**	**1,363.60**	**2,533.02**	**4,404.77**	**4,522.40**	**9,270.84**
Exceptional items	-	-	-	-	-	240.14
Profit before tax	**3,041.17**	**1,363.60**	**2,533.02**	**4,404.77**	**4,522.40**	**9,030.70**
Tax expense						
Current tax	811.97	347.06	637.51	1,159.03	1,138.20	2,413.05
Adjustment of tax relating to earlier periods	40.10	-	-	40.10	-	-
Deferred tax credit	(19.76)	(3.55)	(88.83)	(23.31)	(83.53)	(87.99)
Total tax expense	**832.31**	**343.51**	**548.68**	**1,175.82**	**1,054.67**	**2,325.06**
Profit for the period/year	**2,208.86**	**1,020.09**	**1,984.34**	**3,228.95**	**3,467.73**	**6,705.64**
Other comprehensive income/(loss)						
Items that will not be reclassified subsequently to profit or loss						
Remeasurement (loss)/gain on defined employee benefit plans	(56.51)	9.37	(19.39)	(47.14)	0.69	(20.04)
Income tax effect on above	14.23	(2.36)	4.88	11.87	(0.17)	5.04
	(42.28)	**7.01**	**(14.51)**	**(35.27)**	**0.52**	**(15.00)**
Items that will be reclassified subsequently to profit or loss						
Net (loss)/gain on cash flow hedges	(2.83)	2.83	-	-	-	-
Income tax effect on above	0.71	(0.71)	-	-	-	-
	(2.12)	**2.12**	-	-	-	-
Other comprehensive income/(loss) for the period/year, net of tax	**(44.40)**	**9.13**	**(14.51)**	**(35.27)**	**0.52**	**(15.00)**
Total comprehensive income for the period/year	**2,164.46**	**1,029.22**	**1,969.83**	**3,193.68**	**3,468.25**	**6,690.64**
Paid-up equity share capital (Nominal value of Rs. 2 each)	**1,127.06**	**1,126.77**	**1,123.22**	**1,127.06**	**1,123.22**	**1,123.43**
Other equity						30,723.58
Earnings per share (Nominal value of share Rs. 2 each)						
(Not annualised except for the year ended March 31, 2026)						
Basic	3.92	1.81	3.54	5.74	6.19	11.95
Diluted	3.89	1.80	3.51	5.69	6.12	11.82

See accompaning notes to the Unaudited Standalone Financial Results

Anthem Biosciences Limited Bangalore

S.R. Batliboi & Associates LLP Bengaluru

ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED)

Corporate Identity Number: L24233KA2006PLC039703

Registered and Corporate Office: No 49, F1 and F2, Canara Bank Road, Bommasandra Industrial Area, Phase-1, Bommasandra, Bangalore-560099, Karnataka India.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

Statement of Standalone Assets and Liabilities

(₹. in Million)

Particulars	As at 30.09.2026 Unaudited	As at 31.03.2026 Audited
I Assets		
Non-current assets		
a) Property, plant and equipment	5,950.69	6,096.00
b) Capital work-in-progress	1,288.21	835.22
c) Intangible assets	9.60	4.36
d) Right-of-use assets	22.19	25.26
e) Financial assets		
i) Investments	9,522.67	7,175.44
ii) Trade receivables	31.08	44.56
iii) Loans	2,111.11	2,027.33
iv) Other financial assets	467.23	1,634.63
f) Deferred tax assets (net)	311.56	276.38
g) Income tax assets	132.04	128.57
h) Other non-current assets	388.29	176.68
Total non-current assets	**20,234.67**	**18,424.43**
Current assets		
a) Inventories	1,722.19	1,191.39
b) Financial assets		
i) Investments	6,818.72	6,625.65
ii) Trade receivables	5,085.78	5,729.33
iii) Cash and cash equivalent	193.56	128.37
iv) Bank balances other than (iii) above	6.69	22.34
v) Other financial assets	2,935.83	2,550.79
c) Other current assets	845.35	636.16
Total current assets	**17,608.12**	**16,884.03**
Total assets	**37,842.79**	**35,308.46**
II Equity and liabilities		
Equity		
a) Equity share capital	1,127.06	1,123.43
b) Other equity	33,020.77	30,723.58
Total equity	**34,147.83**	**31,847.01**
Liabilities		
Non-current liabilities		
a) Financial liabilities		
i) Borrowings	194.56	281.98
ii) Lease liabilities	11.52	8.83
iii) Other financial liabilities	169.28	153.78
b) Provisions	253.87	155.19
c) Other non-current liabilities	5.82	7.00
	635.05	**606.78**
Current liabilities		
a) Financial liabilities		
i) Borrowings	189.74	189.74
ii) Lease liabilities	13.58	19.73
iii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	58.36	76.09
- Total outsanding dues of creditors other than micro enterprises and small enterprises	1,432.70	850.80
iv) Other financial liabilities	209.78	242.63
b) Other current liabilities	643.21	898.33
c) Provisions	220.53	204.30
d) Current tax liabilities (net)	292.01	373.05
	3,059.91	2,854.67
Total equity and liabilities	37,842.79	35,308.46

See accompanying notes to the Unaudited Standalone Financial Results

Anthem Biosciences Limited Bangalore

S.R. Batliboi & Associates LLP Bengaluru

ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED)

Corporate Identity Number: L24233KA2006PLC039703

Registered and Corporate Office: No 49, F1 and F2, Canara Bank Road, Bommasandra Industrial Area, Phase-I, Bommasandra, Bangalore-560099, Karnataka India.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

Standalone statement of Cash Flows for half year ended September 30, 2026

(₹. in Million)

Particulars	For the half year ended 30.09.2026 Unaudited	For the half year ended 30.09.2025 Unaudited
Cash flows from operating activities:		
Profit before tax	**4,404.77**	**4,522.40**
Adjustments to reconcile profit before tax to net cash flows		
Depreciation and amortization expense	445.24	465.33
Interest on term loans	12.98	20.04
Interest on cash credit loans	0.76	8.85
Interest on lease liabilities	1.08	1.62
Interest on delayed payment made to MSME vendors	1.81	5.90
Bad debts written off	-	0.12
Impairment allowance on trade receivables	36.04	-
Loss on sale of property, plant and equipment	2.13	0.00
Interest income on deposits, bonds and loans to related parties	(786.65)	(420.06)
Gain on sale of investment in mutual funds, net	(28.88)	(36.86)
Fair value gain on financial assets measured at fair value through profit and loss	(28.62)	(7.20)
Unrealized foreign exchange (gain)/loss	132.18	(131.30)
Amortization of government grant	(1.17)	(1.17)
Share based payment expenses	42.71	79.63
Operating profit before working capital changes	**4,234.38**	**4,507.30**
Adjustment for changes in working capital:		
(Increase)/decrease in other financial assets	(8.69)	34.21
Increase in other assets	(223.19)	(944.61)
Increase in loans	(2.27)	(817.00)
Decrease/(increase) in trade receivables	529.89	(1,208.15)
(Increase)/decrease in inventories	(530.80)	1,707.31
(Decrease)/increase in other financial liabilites	(48.08)	37.59
Increase/(decrease) in trade payables	556.66	(363.26)
(Decrease)/increase in other current liabilities	(295.43)	1,637.84
Increase in provisions	67.76	13.33
Cash generated from operating activities	**4,280.23**	**4,604.56**
Income taxes paid (net of refunds received)	(1,283.63)	(1,115.17)
Net cash generated from operating activities (A)	**2,996.60**	**3,489.39**
Cash flows from investing activities:		
Purchase of property, plant and equipment, capital work-in-progress and intangible assets	(922.37)	(568.98)
Proceeds from sale of property, plant and equipment	1.39	37.54
Redemption in bank deposits (having original maturity of more than 3 months) (net)	1,120.71	-
Redemption/(investment) in earmarked balances with banks (net)	15.64	(675.32)
Purchase of investments in other equity instruments	(15.54)	-
(Purchase)/redemption of investments (mutual funds, bonds, commercial papers and debentures) (net)	(2,466.11)	(1,070.63)
Interest received	375.48	420.21
Net cash used in investing activities (B)	**(1,890.80)**	**(1,857.18)**
Cash flows from financing activities:		
Proceeds from exercise of share options	190.04	255.19
Repayment of borrowings	(101.17)	(54.22)
Payment of principal portion of lease liabilities	(7.63)	(6.05)
Dividend paid to shareholders	(1,126.77)	-
Net cash (used in)/generated from financing activities (C)	**(1,045.53)**	**194.92**
Net increase in cash and cash equivalents (A+B+C)	60.27	1,827.13
Effect of exchange differences on cash and cash equivalents held in foreign currency	4.92	(3.79)
Cash and cash equivalents at the beginning of the period	128.37	3,101.13
Cash and cash equivalents at the end of the period	193.56	4,924.47
Components of cash and cash equivalent:		
Cash on hand	0.00	0.00
Balances with banks		
- in current accounts	193.56	36.41
- in deposit accounts (with orginal maturity less than three months)	-	4,888.06
	193.56	4,924.47

See accompaning notes to the Unaudited Standalone Financial Results

Anthem Biosciences Limited Bangalore

S.R. Batliboi & Associates LLP Bengaluru

Notes to the Unaudited Standalone Financial Results for the Quarter and Half year ended September 30, 2026

1 The Unaudited Standalone Financial Results of Anthem Biosciences Limited (the "Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ("SEBI LODR"), as amended ("Listing Regulations").

2 These Unaudited Standalone Financial Results have been reviewed by the Audit Committee at its meeting held on November 03, 2026 and approved by the Board of Directors of the Company at its meeting held on November 03, 2026.

3 The Board of Directors of the Company at their meeting held on May 19, 2026 had recommended final dividend for the financial year 2025-26 of Rs. 2 per share on face value of Rs. 2 each, aggregating to Rs. 1,126.77 million, which was approved at the Annual General Meeting held on July 22, 2026.

4 During the quarter ended June 30, 2026, the Company has allotted 1,670,909 fully paid-up equity shares of Rs. 2 each under the "Anthem Employee Stock Option Plan 2024" on approval accorded by the Board of Directors of the Company on May 19, 2026 and June 16, 2026.
During the quarter ended September 30, 2026, the Company has allotted 143,285 fully paid-up equity shares of Rs. 2 each under the "Anthem Employee Stock Option Plan 2024" on approval accorded by the Board of Directors of the Company on July 21, 2026 and August 31, 2026

5 Segment information has been presented in the consolidated financial results in accordance with Ind AS 108 notified under Companies (Indian Accounting Standards) Rules, 2015.

6 The above Unaudited Standalone Financial Results of the Company are available on the Company's website (www.anthembio.com) and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf on the Board of Directors of
Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited)
CIN:L24233KA2006PLC039703

Ajay Bhardwaj
Managing Director
DIN: 00333704

Place: Bangalore
Date: November 03, 2026

Anthem Biosciences Limited Bangalore

S.R. Batliboi & Associates LLP Bengaluru

S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants

12th Floor
"UB City" Canberra Block
No. 24, Vittal Mallya Road
Bengaluru - 560 001, India
Tel : +91 80 6648 9000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors . Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.


4. The Statement includes the results of the following entities:
   (i) Anthem Biosciences Limited
   (ii) Neoanthem Lifesciences Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The comparative financial information of the Group for the quarter ended June 30, 2026, quarter and period ended September 30, 2026, included in these consolidated financial results, were reviewed by the predecessor auditor and the Ind AS consolidated financial statements of the Group for the year ended March 31, 2026, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those consolidated financial information on July 21, 2026, November 08, 2025 and May 19, 2026 respectively.

For S.R. Batliboi & Associates LLP
Chartered Accountants
ICAI Firm registration number: 101049W/E300004



per Rajeev Kumar
Partner
Membership No.: 213803

Unique Document Identification Number: 26213803TDLIPB8483

Place: Bengaluru
Date: November 03, 2026

ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED)

Corporate Identity Number: L24233KA2006PLC039703

Registered and Corporate Office: No 49, F1 and F2, Canara Bank Road, Bommasandra Industrial Area, Phase-I, Bommasandra, Bangalore-560099, Karnataka India.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Half year ended September 30, 2026

(₹. in Million)

Particulars	Quarter ended			Half year ended		Year ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	5,940.32	4,182.18	5,505.04	10,122.50	10,913.71	21,293.19
Other income	588.97	248.89	477.52	837.86	699.06	1,507.97
Total income	**6,529.29**	**4,431.07**	**5,982.56**	**10,960.36**	**11,612.77**	**22,801.16**
Expenses						
Cost of materials consumed	2,007.73	1,485.63	2,012.63	3,493.36	3,634.68	7,135.92
Changes in inventories of finished goods and work-in-progress	(160.89)	(23.64)	220.98	(184.53)	907.70	986.91
Employee benefits expense	812.50	788.36	671.91	1,600.86	1,390.61	2,812.44
Finance costs	33.10	8.87	30.55	41.97	47.18	70.54
Depreciation and amortisation expense	307.11	299.87	334.99	606.98	599.45	1,340.70
Other expense	566.01	426.17	415.47	992.18	874.64	1,968.34
Total expense	**3,565.56**	**2,985.26**	**3,686.53**	**6,550.82**	**7,454.26**	**14,314.85**
Profit before exceptional items and tax	**2,963.73**	**1,445.81**	**2,296.03**	**4,409.54**	**4,158.51**	**8,486.31**
Exceptional items	-	-	-	-	-	243.91
Profit before tax	**2,963.73**	**1,445.81**	**2,296.03**	**4,409.54**	**4,158.51**	**8,242.40**
Tax expense						
Current tax	811.98	347.05	637.52	1,159.03	1,138.20	2,413.06
Adjustment of tax relating to earlier periods	40.10	-	-	40.10	-	-
Deferred tax credit	(2.98)	(100.65)	(75.77)	(103.63)	(71.87)	(88.58)
Total tax expense	**849.10**	**246.40**	**561.75**	**1,095.50**	**1,066.33**	**2,324.48**
Profit for the period/year	**2,114.63**	**1,199.41**	**1,734.28**	**3,314.04**	**3,092.18**	**5,917.92**
Other comprehensive income/(loss)						
Items that will not be reclassified subsequently to profit or loss						
Remeasurement (loss)/gain on defined employee benefit plans	(58.06)	9.45	(20.28)	(48.61)	0.12	(20.83)
Income tax effect on above	14.49	(2.37)	4.82	12.12	(0.31)	5.19
	(43.57)	**7.08**	**(15.46)**	**(36.49)**	**(0.19)**	**(15.64)**
Items that will be reclassified subsequently to profit or loss						
Net (loss)/gain on cash flow hedges	(2.83)	2.83	-	-	-	-
Income tax effect on above	0.71	(0.71)	-	-	-	-
	(2.12)	**2.12**	-	-	-	-
Other comprehensive income/(loss) for the period/year, net of tax	**(45.69)**	**9.20**	**(15.46)**	**(36.49)**	**(0.19)**	**(15.64)**
Total comprehensive income for the period/year	**2,068.94**	**1,208.61**	**1,718.82**	**3,277.55**	**3,091.99**	**5,902.28**
Paid-up equity share capital (Nominal value of Rs. 2 each)	**1,127.06**	**1,126.77**	**1,123.22**	**1,127.06**	**1,123.22**	**1,123.43**
Other equity						**29,301.73**
Earnings per share (Nominal value of share Rs. 2 each)						
(Not annualised except for the year ended March 31, 2026)						
Basic	3.75	2.13	3.09	5.89	5.52	10.55
Diluted	3.72	2.11	3.06	5.84	5.45	10.43

See accompaning notes to the Unaudited Consolidated Financial Results

Anthem Biosciences Limited Bangalore

For Batliboi & Associates LLP Bengaluru

ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED)
Corporate Identity Number: L24233KA2006PLC039703

Registered and Corporate Office: No 49, F1 and F2, Canara Bank Road, Bommasandra Industrial Area, Phase-I, Bommasandra, Bangalore-560099, Karnataka India.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

Statement of Consolidated Assets and Liabilities

(₹. in Million)

Particulars	As at 30.09.2026 Unaudited	As at 31.03.2026 Audited
I Assets		
Non-current assets		
a) Property, plant and equipment	7,649.86	7,802.63
b) Capital work-in-progress	3,091.07	2,643.46
c) Intangible assets	9.63	4.41
d) Right of use assets	22.18	25.26
e) Financial assets		
i) Investments	5,764.82	3,418.75
ii) Trade receivables	31.08	31.08
iii) Loans	83.06	73.06
iv) Other financial assets	477.81	1,645.20
f) Deferred tax assets (net)	388.97	273.22
g) Income tax assets	132.04	128.57
h) Other non-current assets	403.63	215.82
Total non-current assets	**18,054.15**	**16,261.46**
Current assets		
a) Inventories	1,885.86	1,245.16
b) Financial assets		
i) Investments	6,846.71	6,655.87
ii) Trade receivables	5,272.38	5,905.88
iii) Cash and cash equivalent	199.84	169.85
iv) Bank balances other than (iii) above	6.69	22.34
v) Other financial assets	2,932.63	2,559.56
c) Other current assets	1,665.54	1,472.78
Total current assets	**18,809.65**	**18,031.44**
Total assets	**36,863.80**	**34,292.90**
II **Equity and liabilties**		
Equity		
a) Equity share capital	1,127.06	1,123.43
b) Other equity	31,682.79	29,301.73
Total equity	**32,809.85**	**30,425.16**
Liabilities		
Non-current liabilities		
a) Financial liabilities		
i) Borrowings	196.85	277.34
ii) Lease liabilities	11.52	8.83
iii) Other financial liabilities	169.28	153.78
b) Provisions	266.80	163.66
c) Other non-current liabilities	5.82	7.00
Total non-current liabilities	**650.27**	**610.61**
Current liabilities		
a) Financial liabilities		
i) Borrowings	189.74	233.34
ii) Lease liabilities	13.58	19.73
iii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	92.42	104.17
- Total outsanding dues of creditors other than micro enterprises and small enterprises	1,559.56	897.74
iv) Other financial liabilities	336.46	429.44
b) Other current liabilities	689.38	990.00
c) Provisions	230.53	209.66
d) Current tax liabilities (net)	292.01	373.05
Total current liabilities	**3,403.68**	**3,257.13**
Total equity and liabilities	**36,863.80**	**34,292.90**

See accompaning notes to the Unaudited Consolidated Financial Results

Anthem Biosciences Limited Bangalore

S R Batliboi & Associates LLP Bengaluru

ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED)

Corporate Identity Number: L24233KA2006PLC039703

Registered and Corporate Office: No 49, F1 and F2, Canara Bank Road, Bommasandra Industrial Area, Phase-I, Bommasandra, Bangalore-560099, Karnataka India.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

Consolidated statement of Cash Flow for half year ended September 30, 2026

(₹. in Million)

Particulars	For the half year ended 30.09.2026 Unaudited	For the half year ended 30.09.2025 Unaudited
Cash flows from operating activities:		
Profit before tax	4,409.54	4,158.50
Adjustments to reconcile profit before tax to net cash flows		
Depreciation and amortization expense	606.98	599.46
Interest on term loans	12.98	20.04
Interest on cash credit loans	0.76	8.85
Interest on lease liabilities	1.08	1.62
Interest on delayed payment made to MSME vendors	3.98	13.79
Bad debts written off	-	0.12
Impairment allowance on trade receivables	36.04	-
Loss on sale of property, plant and equipment	2.13	-
Interest income on deposits, bonds and loans to related parties	(706.37)	(313.17)
Gain on sale of investment in mutual funds, net	(30.64)	(36.86)
Fair value gain on financial assets measured at fair value through profit and loss	(28.82)	(7.20)
Unrealized foreign exchange (gain)/loss	132.41	(131.42)
Amortization of government grant	(1.17)	(1.17)
Share based payment expenses	42.71	79.63
Operating profit before working capital changes	**4,481.61**	**4,392.19**
Adjustment for changes in working capital:		
Decrease in other financial assets	3.24	34.06
Increase in other assets	(206.90)	(1,033.67)
(Increase)/decrease in loans	-	(16.61)
Decrease/(increase) in trade receivables	506.12	(1,106.74)
(Increase)/decrease in inventories	(640.69)	1,546.75
(Decrease)/increase in other financial liabilites	(48.26)	37.59
Increase/(decrease) in trade payables	635.75	(324.84)
(Decrease)/increase in other current liabilities	(340.94)	1,651.73
Increase in provisions	75.39	14.60
Cash generated from operating activities	**4,465.33**	**5,195.06**
Income taxes paid (net of refunds received)	(1,283.63)	(1,115.17)
Net cash generated from operating activities (A)	**3,181.70**	**4,079.89**
Cash flows from investing activities:		
Purchase of property, plant and equipment, capital work-in-progress and intangible assets	(1,105.11)	(998.90)
Proceeds from sale of property, plant and equipment	1.39	37.54
Redemption in bank deposits (having original maturity of more than 3 months) (net)	1,119.80	-
Redemption/(investment) in earmarked balances with banks (net)	15.64	(675.32)
Purchase of investments in other equity instruments	(15.54)	-
(Purchase)/redemption of investments (mutual funds, bonds, commercial papers and debentures) (net)	(2,461.92)	(1,070.63)
Interest received	373.60	313.18
Net cash used in investing activities (B)	**(2,072.14)**	**(2,394.13)**
Cash flows from financing activities:		
Proceeds from exercise of share options	190.04	255.19
Repayment of borrowings	(140.13)	(54.23)
Payment of principal portion of lease liabilities	(7.63)	(6.05)
Dividend paid to shareholders	(1,126.77)	-
Net cash used in/generated from financing activities (C)	**(1,084.49)**	**194.91**
Net (decrease)/increase in cash and cash equivalents (A+B+C)	**25.07**	**1,880.67**
Effect of exchange differences on cash and cash equivalents held in foreign currency	4.92	(3.79)
Cash and cash equivalents at the beginning of the period	169.85	3,161.43
Cash and cash equivalents at the end of the period	**199.84**	5,038.31
Components of cash and cash equivalent:		
Cash on hand	0.01	0.00
Balances with banks		
- in current accounts	199.83	141.99
- in deposit accounts (with orginal maturity less than three months)	-	4,896.32
	199.84	5,038.31

See accompaning notes to the Unaudited Consolidated Financial Results

Anthem Biosciences Limited Bangalore

S.R. Batliboi & Associates LLP Bengaluru

Notes to the Unaudited Consolidated Financial Results for the Quarter and Half year ended September 30, 2026

1 The Unaudited Consolidated Financial Results of Anthem Biosciences Limited (the "Holding Company") together with its subsidiary (collectively the "Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, as amended, read with the Companies (Indian Accounting Standards Rules), 2015, as amended and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), as amended ("Listing Regulations").

2 These Unaudited Consolidated Financial Results have been reviewed by the Audit Committee at its meeting held on November 03, 2026 and approved by the Board of Directors of the Holding Company at its meeting held on November 03, 2026.

3 The Board of Directors of the Company at their meeting held on May 19, 2026 had recommended final dividend for the financial year 2025-26 of Rs. 2 per share on face value of Rs. 2 each, aggregating to Rs. 1,126.77 million, which was approved at the Annual General Meeting held on July 22, 2026.

4 During the quarter ended June 30, 2026, the Company has allotted 1,670,909 fully paid-up equity shares of Rs. 2 each under the "Anthem Employee Stock Option Plan 2024" on approval accorded by the Board of Directors of the Company on May 19, 2026 and June 16, 2026.
During the quarter ended September 30, 2026, the Company has allotted 143,285 fully paid-up equity shares of Rs. 2 each under the "Anthem Employee Stock Option Plan 2024" on approval accorded by the Board of Directors of the Company on July 21, 2026 and August 31, 2026.

5 Based on the internal reporting provided to the Chief Operating Decision Maker, the consolidated financial results relate to "Contract Research, Development and Manufacturing Organization (CRDMO)" and "Speciality Ingredients" as the reportable segments of the Group under the provisions of Ind AS 108 "Operating Segments".

6 The above Unaudited Consolidated Financial Results of the Company are available on the Company's website (www.anthembio.com) and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf on the Board of Directors of
Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited)
CIN:L24233KA2006PLC039703

Ajay Bhardwaj
Managing Director
DIN: 00333704

Place: Bangalore
Date: November 03, 2026

Anthem Biosciences Limited Bangalore

S.R. Batliboi & Associates LLP Bengaluru

ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED)

Corporate Identity Number: L24233KA2006PLC039703

Registered and Corporate Office: No 49, F1 and F2, Canara Bank Road, Bommasandra Industrial Area, Phase-I, Bommasandra, Bangalore-560099. Karnataka India.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

Consolidated segment wise revenue and results for the Quarter and Half year ended September 30, 2026

Segment information - Consolidated

(₹. in Million)

Sl.No	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Segment wise revenue and results:						
I	**Segment revenue:**						
	a) CRDMO	5,092.69	3,408.02	4,662.27	8,500.71	9,195.36	17,774.89
	b) Speciality Ingredients	847.63	774.16	842.77	1,621.79	1,718.35	3,518.30
	Total	**5,940.32**	**4,182.18**	**5,505.04**	**10,122.50**	**10,913.71**	**21,293.19**
II	**Segmental results:**						
	a) CRDMO	3,662.62	2,322.57	2,858.60	5,985.19	5,513.30	11,377.06
	b) Speciality Ingredients	430.86	397.62	412.84	828.49	858.04	1,793.31
	Total	**4,093.48**	**2,720.19**	**3,271.44**	**6,813.68**	**6,371.34**	**13,170.37**
	Less: Selling and un-allocable expenditure net of other income	1,129.75	1,274.38	975.41	2,404.14	2,212.83	4,927.97
	Total profit before tax:	**2,963.73**	**1,445.81**	**2,296.03**	**4,409.54**	**4,158.51**	**8,242.40**

Note:

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

For and on behalf on the Board of Directors of

Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited)

CIN:L24233KA2006PLC039703

Ajay Bhardwaj
Managing Director
DIN: 00333704

Place: Bangalore
Date: November 03, 2026

Anthem Biosciences Limited Bangalore

S.R. Batliboi & Associates LLP Bengaluru